The Signal and the Service: Decoding the New Alliance in Veteran Lung Health

SAN ANTONIO, TX – June 16, 2026 – On the surface, it’s a press release about a webinar. A trio of companies—bioAffinity Technologies, Philips, and 4DMedical—are gathering experts to discuss lung health for U.S. veterans. But in the world of corporate strategy, such events are rarely just educational. They are signals. This collaboration is a calculated response to one of the most significant shifts in American veteran healthcare in a generation: the PACT Act. It signals a convergence of advanced technology, public policy, and immense market opportunity, all aimed at a population bearing the unseen scars of service.

What we are witnessing is the formation of a potential end-to-end solution for a crisis that has been decades in the making. By deconstructing the players, the technology, and the timing, we can see the outline of a new strategy to tackle a complex and deeply entrenched health disparity.

The Unseen Battlefield: Veteran Lung Health in the Post-PACT Era

The landscape of veteran healthcare was fundamentally reshaped in 2022 with the passage of the Promise to Address Comprehensive Toxics (PACT) Act. This landmark legislation acknowledged the devastating long-term health consequences of toxic exposures—from the infamous burn pits of Iraq and Afghanistan to the Agent Orange of Vietnam and asbestos-laden naval ships. The Act designated over 20 respiratory illnesses and cancers as “presumptive conditions,” meaning veterans no longer face the arduous task of proving a direct link between their service and their sickness to receive care and benefits.

This policy shift is staggering in its scale. The Department of Veterans Affairs (VA) estimates that millions of veterans are now eligible for expanded care. The numbers paint a grim picture of the need. Veterans face a lung cancer incidence rate that is anywhere from 25% to 76% higher than their civilian counterparts. Each year, roughly 8,000 veterans are diagnosed with the disease, a diagnosis often complicated by a history of both higher smoking rates and unique, service-related exposures. The PACT Act has effectively opened the floodgates, creating an urgent demand for effective, scalable screening and diagnostic solutions within the VA system.

Traditional screening, primarily low-dose computed tomography (LDCT), has struggled with low uptake among the 1.4 million eligible veterans. The challenge is clear: how do you effectively screen a massive, high-risk population, identify disease at its earliest and most treatable stage, and avoid subjecting veterans to unnecessary, costly, and often risky invasive procedures?

A New Arsenal for Early Detection

This is the problem the new alliance aims to solve. The webinar, moderated by the CEO of the National Association of Veterans’ Research and Education Foundations (NAVREF), is a showcase of a new technological arsenal. At the forefront is bioAffinity Technologies’ CyPath® Lung, a non-invasive test that represents a significant departure from conventional diagnostics.

Instead of relying solely on imaging, CyPath® Lung analyzes a patient's sputum—a mixture of saliva and mucus from the respiratory tract. It uses advanced flow cytometry and an AI-driven algorithm to analyze cell populations. The test’s ingenuity lies in its use of a fluorescent porphyrin, a compound that is preferentially absorbed by cancer and cancer-related cells, making them glow under examination. In a clinical trial involving high-risk patients with small, indeterminate lung nodules, the test demonstrated 92% sensitivity and 87% specificity. More importantly for both patient and physician, it showed a 99% negative predictive value (NPV). In simple terms, this high NPV provides powerful reassurance that a negative result is truly negative, potentially saving a veteran from an unnecessary and stressful follow-up biopsy.

Complementing this diagnostic tool is the advanced imaging capability of 4DMedical. While traditional CT scans provide a static, structural image of the lungs, 4DMedical’s XV Technology creates a dynamic, four-dimensional map of lung function. It visualizes the actual motion and airflow through the lungs during breathing, revealing functional deficits that can be missed by standard scans. This is achieved with a radiation dose equivalent to a single chest X-ray, a critical consideration for any screening program. This technology moves the needle from merely finding a suspicious nodule to understanding its functional impact and the health of the surrounding tissue, enabling earlier and more precise detection of diseases like COPD and pulmonary fibrosis—both presumptive conditions under the PACT Act.

The Strategic Alliance: Reading the Corporate Signals

The collaboration itself is the most telling signal. This isn't a case of three disparate companies coincidentally sharing a stage. It’s a strategic alignment of complementary capabilities, orchestrated to address a specific, large-scale market need. bioAffinity brings the non-invasive, AI-powered diagnostic. 4DMedical provides the next-generation functional imaging. And Philips, the global health technology giant, brings the scale, integration platform, and—most crucially—the relationships.

Philips’ involvement is not a casual foray. The company has a deeply embedded, 50-year partnership with the U.S. military and the VA. It built and helps operate the world's largest tele-critical care network for the VA, a system that provides remote ICU expertise to veterans across the country. Its portfolio includes the Azurion Lung Edition, an advanced 3D imaging and navigation platform designed to accelerate lung cancer diagnosis and treatment. By joining this webinar, Philips is signaling its intent to act as the integrator, a powerful platform through which cutting-edge technologies like CyPath® Lung and 4DMedical's imaging can be deployed across its vast network.

The presence of Dr. Amy Rohs, a Philips physician champion and former VA clinical leader, and Dr. Greg Mogel, 4DMedical’s Chief Medical Officer and an Army Medical Corps veteran, further underscores the focused intent. This alliance is speaking the VA’s language, demonstrating an intrinsic understanding of the veteran community’s needs and the operational realities of its healthcare system.

The webinar, therefore, is a public demonstration of a potential workflow: a veteran with a positive screening or symptoms could receive a non-invasive CyPath® Lung test. If further investigation is needed, 4DMedical's advanced imaging could provide detailed functional analysis, all potentially integrated within the Philips ecosystem that the VA already knows and uses. It’s a powerful, synergistic value proposition. The success of this initiative will ultimately be measured not by the sophistication of its technology, but by its ability to navigate the complex healthcare landscape and reach the veterans who need it most.